Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Lancet Oncology

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(14)70281-5PMID 25008258PMCID PMC4137593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

  2014cited by this paper
• The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

  2014cited by this paper
• Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.

  2014cited by this paper
• Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

  2013cited by this paper
• The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

  2013cited by this paper
• Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta‐analysis

  2013cited by this paper
• Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531

  2013cited by this paper
• A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

  2013cited by this paper
• Gemtuzumab ozogamicin: time to resurrect?

  2012cited by this paper
• Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

  2012cited by this paper
• Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

  2012cited by this paper
• Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.

  2012cited by this paper
• Minimal Residual Disease Assessed by WT1 Expression and NPM1 Mutations Specific RQ-PCR Assays Identifies Patients with Distinct Outcomes in the ALFA 0701 Trial and Is Decreased by Treatment with Gemtuzumab Ozogamicin

  2012cited by this paper
• Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

  2011cited by this paper
• Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study

  2011cited by this paper
• Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

  2010cited by this paper
• Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

  2008cited by this paper
• High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

  2007cited by this paper
• Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

  2005cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

  2003cited by this paper
• Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy

  2002cited by this paper
• Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

  2002cited by this paper
• Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

  2001cited by this paper
• Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

  2001cited by this paper
• Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.

  2001cited by this paper

• Effect of pretransplant spleen volume on the prognosis of acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.

  2026cites this paper
• Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives

  2026cites this paper
• Molecularly targeted therapy and immunotherapy in leukemias

  2026cites this paper
• Leukemia cutis as the first manifestation of acute myeloid leukemia.

  2026cites this paper
• Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT).

  2026cites this paper
• Ready, set, GO? Treating older adults with AML.

  2026cites this paper
• Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML

  2025cites this paper
• A Comprehensive Genomic Analysis of Nucleophosmin (NPM1) in Acute Myeloid Leukemia

  2025cites this paper
• Evolving Paradigms in Acute Myeloid Leukemia: Personalized Approaches to Therapy Across Age and Risk Groups

  2025influential citation
• Outcomes with intensive chemotherapy, compared to hypomethylating agent + venetoclax, in patients with intermediate and adverse risk acute myeloid leukemia.

  2025cites this paper
• Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies

  2025influential citation
• Biology and Management of Acute Myeloid Leukemia With Mutated NPM1

  2025cites this paper
• Base edited “universal” donor CAR T-cell strategies for acute myeloid leukaemia

  2025cites this paper
• Tailoring intensive and less-intensive treatment in acute myeloid leukemia.

  2025cites this paper
• Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistry

  2025cites this paper
• Patient-Centered Genomic Diagnostic Testing for AML: A Quality Improvement Project.

  2025cites this paper
• Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management

  2025cites this paper
• Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia

  2025cites this paper
• Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study

  2025cites this paper
• Immunotherapy in chronic lymphocytic leukemia: advances and challenges

  2025cites this paper
• Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions

  2025cites this paper
• A Case of Cryptic CBFB::MYH11 Acute Myeloid Leukemia With Noncanonical Breakpoints Detected by Optical Genome Mapping.

  2025cites this paper
• Autologous or allogeneic hematopoietic stem cell transplantation as front-line treatment for adult secondary acute myeloid leukemia patients: the PETHEMA registry experience.

  2025cites this paper
• Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis

  2025cites this paper
• Bispecific Antibodies and Antibody–Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma

  2025cites this paper
• Impact of European LeukemiaNet–guided postremission therapy on outcomes of patients with AML from 2010 to 2022

  2025cites this paper
• Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML

  2025cites this paper
• Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

  2025cites this paper
• A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

  2025cites this paper
• A Danish nationwide population-based cohort study on acute myeloid leukemia with RUNX1::RUNX1T1 – Real-world outcomes and clinicopathological characteristics

  2025cites this paper
• DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody–Drug Conjugates for Acute Leukemia

  2025cites this paper
• Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience

  2025cites this paper
• Where do immunotherapies stand in management of acute leukemia in adults?

  2025cites this paper
• Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies

  2025cites this paper
• Novel therapies for acute myeloid leukemia. Does age still matter?

  2025cites this paper
• Preclinical targeting of leukemia-initiating cells in the development future biologics for acute myeloid leukemia

  2025cites this paper
• A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond

  2025cites this paper
• Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach

  2025cites this paper
• Central nervous system relapse of core-binding factor acute myeloid leukemia

  2025cites this paper
• Acute Myeloid Leukemia with Core-Binding Factor Rearrangements: A 10-Year Cancer Center Experience

  2025cites this paper
• Revisiting the Role of Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia

  2025cites this paper
• Targeting myeloid cells for hematological malignancies: the present and future

  2025cites this paper
• Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges

  2025cites this paper
• Predictive Model of Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia on Event-Free Survival: Data Analysis Based on Trial AAML0531

  2025cites this paper
• Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics

  2025cites this paper
• Management der akuten myeloischen Leukämie im höheren Alter

  2025cites this paper
• Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries

  2025cites this paper
• Real‐world experience with CPX‐351 for secondary acute myeloid leukaemia: Comparison with FLAG‐IDA in a propensity score matching analysis

  2025cites this paper
• Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents

  2025cites this paper
• Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of “Rete Ematologica Pugliese” (REP)

  2025cites this paper
• NPM1-Mutated AML: Deciphering the Molecular and Clinical Puzzle in the Era of Novel Treatment Strategies

  2025cites this paper
• Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML

  2025cites this paper
• White blood cell count as a powerful prognostic marker and treatment guide in paediatric acute myeloid leukaemia with NUP98 rearrangement

  2025cites this paper
• The continuing search for effective treatments for older adults with acute myeloid leukemia

  2025cites this paper
• Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia.

  2025cites this paper
• Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia

  2025cites this paper
• Does Time Matter From Diagnosis to Induction in Acute Myeloid Leukemia?

  2025cites this paper
• Acute myeloid leukemia in the next-generation sequencing era

  2024cites this paper
• Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoring

  2024cites this paper
• AML in the Elderly – When less may be more

  2024cites this paper
• Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead

  2024cites this paper
• How I Treat: Secondary Acute Myeloid Leukemia.

  2024cites this paper
• Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy

  2024influential citation
• Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia

  2024cites this paper
• Current status and research directions in acute myeloid leukemia

  2024influential citation
• Breaking Boundaries: Immunotherapy for Myeloid Malignancies

  2024cites this paper
• Unveiling the Role of New Molecules in Acute Myeloid Leukemia: Insights into Disease Pathogenesis and Therapeutic Potential

  2024cites this paper
• Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead

  2024cites this paper
• Contemporary Management of Acute Myeloid Leukemia: A Review.

  2024cites this paper
• Targeting the Tumour Antigen 5T4 using CAR-T Cells for the Treatment of Acute Myeloid Leukaemia.

  2024cites this paper
• Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia

  2024cites this paper
• Update of antibody–drug conjugates for hematological malignancies

  2024cites this paper
• CREST‐UK: Real‐world effectiveness, safety and outpatient delivery of CPX‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK

  2024cites this paper
• Chimeric antigen receptor T-cell therapy in acute myeloid leukaemia: Novel therapeutic approaches to longstanding challenges

  2024cites this paper
• Navigating Treatment Options and Communication in Relapsed Pediatric AML.

  2024cites this paper
• The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View

  2024cites this paper
• Advancements and Challenges in the Treatment of AML.

  2024cites this paper
• Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia

  2024cites this paper
• Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy

  2024cites this paper
• Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate

  2024cites this paper
• Transplant Eligible and Ineligible Elderly Patients with AML—A Genomic Approach and Next Generation Questions

  2024cites this paper
• Antibody drug conjugates in the clinic

  2024cites this paper
• How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?

  2024cites this paper
• High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia

  2024cites this paper
• Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window.

  2024cites this paper
• Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.

  2024cites this paper
• Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates.

  2024cites this paper
• Novel Four-Way t(8;14;15;21)(q22;q22;q15;q22.1) Translocation Variant in Acute Myeloid Leukemia with RUNX1::RUNX1T1

  2024cites this paper
• Association between Serum Lactate Dehydrogenase Level and 30-day Mortality in Patients with Intracranial Hemorrhage with Acute Leukemia in the Induction Phase: A Cohort Study

  2024cites this paper
• New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches

  2024influential citation
• Real-world treatment outcomes from a retrospective cohort of patients with acute myeloid leukemia from an urban safety net hospital

  2024cites this paper
• Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia

  2024cites this paper
• Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

  2024cites this paper
• Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective.

  2024cites this paper
• Targeting the DNA damage response in hematological malignancies

  2024cites this paper
• Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191

  2024cites this paper
• Concurrent BCR‐ABL1 and core binding factor beta rearrangement in de novo acute myeloid leukemia: A case report and review of literature

  2024cites this paper
• Optimizing combination targeted immunotoxin therapy: Insights from HER2 and EpCAM expression profiles.

  2024cites this paper
• Acute myeloid leukemia

  2024cites this paper
• Navigating AML treatment in vascular Ehlers–Danlos syndrome: achieving deeper remission with oral azacitidine—a first case report

  2024influential citation